Clinical Trial Update: Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating GSK's 2189242A vaccine for safety, immunogenicity, and impact on nasopharyngeal carriage in children and infants; results posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infectious Diseases
• Streptococcal Infections

Drugs mentioned

• 2189242A vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Streptococcal | Phase 2 | Status: COMPLETED | Results posted: 2014-04-21